A Phase 1, Randomized, Open-Label, Single Dose Cross-Over Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine).
Phase of Trial: Phase I
Latest Information Update: 19 Jan 2010
At a glance
- Drugs Latrepirdine (Primary)
- Indications Alzheimer's disease; Huntington's disease
- Focus Pharmacokinetics
- Sponsors Pfizer
- 13 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Dec 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 27 Oct 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.